drugset / Trial / NCT00313053
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. The trial will study the safety, pharmacokinetics, and anti-tumor activity of the antibody given as a single agent and with vincristine.
Timeline
- Start
- 2004-09
- Primary completion
- 2008-04
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human mAb 216 | Monoclonal antibody | — | Other |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |